William Blair Weighs in on Exact Sciences Corporation’s FY2017 Earnings (EXAS)

Exact Sciences Corporation (NASDAQ:EXAS) – Analysts at William Blair raised their FY2017 earnings estimates for Exact Sciences Corporation in a research report issued to clients and investors on Monday. William Blair analyst B. Weinstein now expects that the medical research company will post earnings per share of ($1.12) for the year, up from their prior forecast of ($1.20). William Blair also issued estimates for Exact Sciences Corporation’s Q4 2017 earnings at ($0.31) EPS, Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.18) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.03) EPS and FY2018 earnings at ($0.54) EPS.

Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. During the same period in the prior year, the firm earned ($0.36) EPS. The company’s revenue was up 158.4% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/11/03/william-blair-weighs-in-on-exact-sciences-corporations-fy2017-earnings-exas.html.

Several other research analysts have also recently issued reports on EXAS. Leerink Swann reaffirmed an “outperform” rating and issued a $63.00 target price (up from $50.00) on shares of Exact Sciences Corporation in a report on Tuesday. Benchmark Co. reaffirmed a “buy” rating and issued a $60.00 target price (up from $50.00) on shares of Exact Sciences Corporation in a report on Tuesday. Canaccord Genuity upgraded shares of Exact Sciences Corporation to a “buy” rating and set a $60.00 price target for the company in a research note on Tuesday. Craig Hallum lifted their price target on shares of Exact Sciences Corporation from $46.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Robert W. Baird lifted their price target on shares of Exact Sciences Corporation from $49.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $49.71.

In related news, insider Graham Peter Lidgard sold 45,775 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $41.49, for a total transaction of $1,899,204.75. Following the completion of the sale, the insider now directly owns 288,952 shares in the company, valued at $11,988,618.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas D. Carey bought 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average price of $37.71 per share, with a total value of $94,275.00. Following the completion of the transaction, the director now directly owns 60,858 shares of the company’s stock, valued at approximately $2,294,955.18. The disclosure for this purchase can be found here. Insiders have sold 231,598 shares of company stock valued at $10,182,030 over the last 90 days. 4.00% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in EXAS. Fortaleza Asset Management Inc. bought a new stake in Exact Sciences Corporation during the second quarter valued at approximately $106,000. Krilogy Financial LLC grew its position in Exact Sciences Corporation by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after buying an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after buying an additional 600 shares during the period. Financial Architects Inc grew its position in Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after buying an additional 2,035 shares during the period. Finally, Johnson Financial Group Inc. grew its position in Exact Sciences Corporation by 25.9% during the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after buying an additional 1,000 shares during the period. Institutional investors own 85.12% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

What are top analysts saying about Exact Sciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exact Sciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit